Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled

Ingelheim, Germany (5. April 2011) – In the business year 2010, Boehringer Ingelheim almost compensated for the anticipated loss of turnover announced in advance last year, nearly achieving the previous year‘s level. Despite the sales loss of EUR 1.4 billion, due to the loss of exclusivity rights on important sales drivers in the US pharmaceuticals market, and the additional burden arising from healthcare reforms in the USA and Europe, business developed satisfactorily in 2010. This can be put down to growth in the rest of the Prescription Medicines portfolio (currency-adjusted +5.5 percent), the successful launch of new products and a sharp 51 percent increase in sales in the Animal Health business. Operating income, comparable to EBIT, was satisfactory at around EUR 1.9 billion, corresponding to a return on net sales (operating income in relation to net sales) of 15.1 percent. For Boehringer Ingelheim, 2010 was thus a successful year, in spite of the difficult overall conditions.